Key Points
- CEO Jack Bendheim sold multiple blocks of PAHC stock in February totaling roughly $11.7 million, reducing his direct stake to 15,560 shares valued at about $799,317.
- Phibro beat quarterly expectations, reporting EPS of $0.87 versus a $0.69 estimate and revenue of $373.9M versus $355.6M, and set FY2026 guidance of 2.93–3.10 EPS.
- Dividend announced: a quarterly payout of $0.12 per share (annualized $0.48) with an ex-dividend date of March 4 and a yield of ~0.9%.
Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) CEO Jack Bendheim sold 7,040 shares of the stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $51.37, for a total transaction of $361,644.80. Following the transaction, the chief executive officer directly owned 15,560 shares of the company's stock, valued at $799,317.20. This trade represents a 31.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Jack Bendheim also recently made the following trade(s):
- On Thursday, February 26th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $53.73, for a total value of $378,259.20.
- On Friday, February 20th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.42, for a total value of $361,996.80.
- On Wednesday, February 18th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.40, for a total value of $361,856.00.
- On Friday, February 13th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.96, for a total value of $365,798.40.
- On Wednesday, February 11th, Jack Bendheim sold 14,184 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.62, for a total transaction of $732,178.08.
- On Tuesday, February 10th, Jack Bendheim sold 58,014 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.81, for a total transaction of $3,005,705.34.
- On Thursday, February 5th, Jack Bendheim sold 110,842 shares of Phibro Animal Health stock. The shares were sold at an average price of $48.38, for a total transaction of $5,362,535.96.
- On Wednesday, February 4th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.15, for a total transaction of $144,848.00.
- On Tuesday, February 3rd, Jack Bendheim sold 9,660 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.47, for a total transaction of $400,600.20.
- On Friday, January 30th, Jack Bendheim sold 6,693 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.09, for a total transaction of $268,322.37.
Phibro Animal Health Trading Up 3.0%
Shares of NASDAQ PAHC opened at $54.70 on Friday. Phibro Animal Health Corporation has a 1-year low of $16.16 and a 1-year high of $56.30. The company has a debt-to-equity ratio of 2.14, a current ratio of 3.05 and a quick ratio of 1.22. The business's 50 day moving average is $43.41 and its two-hundred day moving average is $40.66. The stock has a market capitalization of $2.22 billion, a P/E ratio of 24.31, a PEG ratio of 0.82 and a beta of 0.80.
Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.18. The business had revenue of $373.91 million during the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. As a group, research analysts expect that Phibro Animal Health Corporation will post 1.95 EPS for the current year.
Phibro Animal Health Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Wednesday, March 4th will be paid a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Wednesday, March 4th. Phibro Animal Health's payout ratio is presently 21.33%.
Hedge Funds Weigh In On Phibro Animal Health
A number of institutional investors have recently modified their holdings of PAHC. 1620 Investment Advisors Inc. boosted its holdings in shares of Phibro Animal Health by 77.4% in the fourth quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company's stock valued at $25,000 after purchasing an additional 295 shares during the period. Farther Finance Advisors LLC increased its holdings in Phibro Animal Health by 113.2% during the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company's stock worth $27,000 after purchasing an additional 386 shares during the period. Hughes Financial Services LLC bought a new stake in Phibro Animal Health during the 3rd quarter valued at $40,000. Rothschild Investment LLC lifted its holdings in shares of Phibro Animal Health by 2,500.0% in the 4th quarter. Rothschild Investment LLC now owns 1,040 shares of the company's stock worth $39,000 after buying an additional 1,000 shares during the period. Finally, iSAM Funds UK Ltd purchased a new stake in shares of Phibro Animal Health in the 3rd quarter worth $61,000. 99.34% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
PAHC has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. lifted their price target on shares of Phibro Animal Health from $45.00 to $50.00 and gave the stock an "overweight" rating in a research note on Friday, November 7th. Weiss Ratings reissued a "buy (b-)" rating on shares of Phibro Animal Health in a research note on Monday, December 29th. Zacks Research cut Phibro Animal Health from a "strong-buy" rating to a "hold" rating in a research note on Monday, February 9th. Finally, Morgan Stanley set a $49.00 price target on Phibro Animal Health in a research note on Friday, February 6th. Two analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $37.50.
Check Out Our Latest Stock Analysis on Phibro Animal Health
About Phibro Animal Health
(
Get Free Report)
Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.
The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
